Table 2.
Analyses of the samples obtained at the different time points
| Time point 1, n = 25 | Time point 2, n = 25 | Time point 3, n = 19 | Total, n = 69 | |
|---|---|---|---|---|
| Actual time since start of imatinib [days]a | 30 (3) | 97 (30) | 364 (20) | |
| AGP level [g/L]b | 0.97 (0.85–1.10) | 0.81 (0.69–0.94) | 0.89 (0.78–1.00) | 0.89 (0.82–0.96) |
| Imatinib concentration [ng/mL]b | 1457 (1155–1838) | 1305 (1001–1702) | 1193 (967–1472) | 1325 (1158–1516) |
| CGP74588 concentration [ng/mL]b | 308 (247–384) | 265 (205–343) | 231 (179–299) | 270 (235–309) |
| Imatinib + CGP74588 concentration [ng/mL]b | 1777 (1420–2224) | 1578 (1217–2047) | 1439 (1165–1777) | 1606 (1407–1833) |
| Correlation between imatinib and AGPc | 0.526 (P < 0.001) | 0.839 (P < 0.001) | 0.411 (P = 0.003) | 0.656 (P < 0.001) |
The three time points are the times at which sampling was scheduled according to the protocol, i.e. 30 days, 90 days and 365 days after the start of treatment
AGP alpha-1 acid glycoprotein
aUnits of time are presented as mean (standard deviation)
bValues are presented as geometric mean (95 % confidence interval)
cCorrelations are depicted as r 2 (P value)